Characterizing the outcomes of metastatic papillary renal cell carcinoma

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

Cancer medicine. 2017 Apr 16 [Epub ahead of print]

John Connor Wells, Frede Donskov, Anna P Fraccon, Felice Pasini, Georg A Bjarnason, Benoit Beuselinck, Jennifer J Knox, Sun Young Rha, Neeraj Agarwal, Isaac Alex Bowman, Jae-Lyun Lee, Sumanta K Pal, Sandy Srinivas, Douglas Scott Ernst, Ulka N Vaishampayan, Lori A Wood, Robin Simpson, Guillermo De Velasco, Toni K Choueiri, Daniel Y C Heng

Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Aarhus University Hospital, Aarhus, Denmark., Casa di Cura Pederzoli, Peschiera Del Garda, Italy., Medical Oncology Department, Ospedale Santa Maria della Misericordia, Rovigo, Italy., Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada., University Hospitals Leuven, Leuven, Belgium., Princess Margaret Hospital, Toronto, Ontario, Canada., Yonsei University College of Medicine, Seoul, South Korea., Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., University of Texas Southwestern Medical Center, Dallas, Texas., Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea., City of Hope Comprehensive Cancer Center, Duarte, California., Stanford Cancer Center, Stanford, California., London Health Sciences Center, London, Ontario, Canada., Karmanos Cancer Institute, Detroit, Michigan., Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada., Dana Farber Cancer Institute, Boston, Massachusetts.